Compare Ginkgo Bioworks Holdings Inc (DNA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Paychex, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.02 (market cap $590.53M), while Paychex, Inc. trades at $109.85 (market cap $38.95B). The key difference: Paychex, Inc. is far larger — about 66× Ginkgo Bioworks Holdings Inc's market cap, and Paychex, Inc. pays a 4.35% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | PAYX | |
|---|---|---|
Market Cap | $590.53M | $38.95B |
Sector | Health | Industrials |
52-Week High | $16.14 | $147.99 |
52-Week Low | $5.48 | $85.57 |
Enterprise Value | $627.78M | $42.43B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Paychex (PAYX) trades at $110.75, up 2.98% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations, and maintains robust profitability with 27.03% net income margin. Recent dividend payment of $1.19 and positive business momentum from AI expansion and small business hiring trends support growth outlook.
Outlook remains positive with steady revenue growth and AI-driven efficiency gains, though valuation multiples appear elevated with P/E of 22.65. Risks include competitive pressures and macroeconomic sensitivity to small business employment trends. Analyst consensus is mixed with 16.67% buy ratings but price target alignment with current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
